The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway

(L597V)BRAF mutations are acquired somatically in human cancer samples and are frequently coincident with RAS mutations. Germline (L597V)BRAF mutations are also found in several autosomal dominant developmental conditions known as RASopathies, raising the important question of how the same mutation...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Andreadi, Catherine, Cheung, Lai-Kay, Giblett, Susan, Patel, Bipin, Jin, Hong, Mercer, Kathryn, Kamata, Tamihiro, Lee, Pearl, Williams, Alexander, McMahon, Martin, Marais, Richard, Pritchard, Catrin
Natura: Artigo
Lingua:Inglês
Pubblicazione: Cold Spring Harbor Laboratory Press 2012
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3435497/
https://ncbi.nlm.nih.gov/pubmed/22892241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/gad.193458.112
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi